NeuOrphan has discovered a potential treatment for progressive multiple sclerosis.
This research may enhance the Quality-of-Life outcomes for individuals living with MS.
When the drug was used on a mouse model of MS it protected the spinal cord and optic nerve from damage.
Importantly, we showed that the drug promoted mouse and human brain cells to enhance repair through remyelination and paralysed mice were able to walk again.
Timeline to commercialization:
NeuOrphan Pty Ltd is currently scaling up its corporate and commercial sector to achieve a successful listing via an Initial Public Offering (IPO), raising a minimum of $15 million in funds over the next 6 months.
Fast track for DITPA to enter a Phase II Clinical Trial study for progressive MS involving a patient group of between 1,000 and 1,300. The trial period is projected to last upwards of one year.
The trial will commence in early 2024 and engagement with the required partners to effectively deliver the Phase II Clinical Trial is in place.
We are currently focused on the development of a novel drug for multiple sclerosis and other neurological disorders. Our goal is to complete the preclinical stage and start clinical phase 2 trials in 2024.
In the future, we plan to expand our research to other neurodegenerative diseases and develop more innovative treatments. Our aim is to make a real difference in the lives of patients worldwide.
We believe in the power of collaboration. We are actively seeking partnerships with other biotech companies, research institutions, and investors to accelerate the development and commercialization of our drug.